| Ytd | -39.51% | |
| 1y | 179.38% |
| Open | 5.68 | Prev Close | 5.68 | Low | 5.33 | High | 5.92 | Mkt Cap | 1.89B |
| Vol | 7.39M | Avg Vol | 5.45M | EPS | -0.43 | P/E | N/A | Forward P/E | -94.42 |
| Beta | 1.56 | Short Ratio | 10.53 | Inst. Own | 64.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 4.95 | 200-d Avg | 5.42 | 1yr Est | 12.33 |
According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company f
U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a
Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tacklin
NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on